Plus, news about Skye Bioscience and Vera Therapeutics:
Ascendis Pharma, investors spin out eye care company: Eyconis, based in Redwood City, CA, will develop, manufacture and commercialize the company’s ophthalmology assets, as previously disclosed. The investor group includes Frazier Life Sciences, RA Capital Management, venBio and HealthQuest Capital. Ascendis has granted Eyeconis the rights to develop and commercialize its eye care products, and the Danish drugmaker can also receive milestones up to $248 million, plus single-digit royalty on product sales. “Because of the broad applicability of the technology platform, potentially some of this element are much better managed in acceleration where there is a dedicated, high level, high knowledgeable ophthalmology leadership,” CEO Jan Mikkelsen told investors at the JP Morgan Healthcare Conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.